La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Extrawell Pharmaceutical Holdings Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Extrawell Pharmaceutical Holdings ha un patrimonio netto totale di HK$1.1B e un debito totale di HK$117.1M, che porta il suo rapporto debito/patrimonio netto a 10.5%. Le sue attività totali e le sue passività totali sono rispettivamente HK$1.3B e HK$174.6M.

Informazioni chiave

10.5%

Rapporto debito/patrimonio netto

HK$117.12m

Debito

Indice di copertura degli interessi	n/a
Contanti	HK$95.01m
Patrimonio netto	HK$1.11b
Totale passività	HK$174.58m
Totale attività	HK$1.29b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Mar 18

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

Dec 01

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Aug 04

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Mar 15

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Aug 20

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( HK$177.4M ) di 858 superano le sue passività a breve termine ( HK$51.4M ).

Passività a lungo termine: Le attività a breve termine di 858 ( HK$177.4M ) superano le sue passività a lungo termine ( HK$123.2M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 2% ) di 858 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 858 è aumentato da 4.7% a 10.5% negli ultimi 5 anni.

Copertura del debito: Il flusso di cassa operativo di 858 è negativo, pertanto il debito non è ben coperto.

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di 858 siano ben coperti dall'EBIT.

Extrawell Pharmaceutical Holdings Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Recent updates

Full year 2024 earnings released: HK$0.068 loss per share (vs HK$0.054 profit in FY 2023)

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 23, 2024

Full year 2024 earnings released: HK$0.068 loss per share (vs HK$0.054 profit in FY 2023)

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Jun 28, 2024

Extrawell Pharmaceutical Holdings Limited Announces Board and Committee Changes

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

New major risk - Share price stability

New major risk - Market cap size

First half 2024 earnings released: HK$0.099 loss per share (vs HK$0.019 profit in 1H 2023)

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

New major risk - Revenue and earnings growth

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Nov 29, 2023

New minor risk - Share price stability

Full year 2023 earnings released: EPS: HK$0.054 (vs HK$0.055 in FY 2022)

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 25, 2023

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: HK$0.054 (vs HK$0.055 in FY 2022)

New minor risk - Financial data availability

Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

Extrawell Pharmaceutical Holdings Limited Announces Demise of Mr. Xue Jing Lun, Independent Non-Executive Director, and A Member of Each of the Audit Committee, Remuneration Committee and Nomination Committee

First half 2023 earnings released: EPS: HK$0.019 (vs HK$0.037 in 1H 2022)

Extrawell Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 September 2022

Less than half of directors are independent

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Nov 29, 2022

Extrawell Pharmaceutical Holdings Limited Announces Management Changes

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Full year 2022 earnings released: EPS: HK$0.055 (vs HK$0.051 loss in FY 2021)

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 30, 2022

Full year 2022 earnings released

Extrawell Pharmaceutical Holdings Limited Provides Earnings Guidance for the Year Ended March 31, 2022

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Full year 2021 earnings released: HK$0.051 loss per share (vs HK$0.035 profit in FY 2020)

Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended March 31, 2021

First half 2021 earnings released: EPS HK$0.031

First half 2021 earnings released: EPS HK$0.031

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2021 Results on Nov 27, 2020

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane